Introduction

Post Coronavirus Disease-19 (COVID-19) radiography features has altered features. There are few types including ground glass opacities (GGO) and fibrosis as sequelae features. The previous history of therapy when patients were hospitalized is one of suspected factor in relation to those alterations.

Aims and objectives

The hypothesis is an appearance of sequelae in HRCT consists of GGO and fibrotic lesion has correlation to antiviral, anti-inflammatory, and anti-thrombotic therapy were given to patients.

Methods

This is a retrospective cohort study with 52 post-COVID-19 patients as subjects in Persahabatan General Hospital, Indonesia. Patients are then followed up in 4th-12th weeks after first symptoms onset for post COVID-19 lesion in radiography features. The inclusion criteria previous history of antiviral (favipiravir (F) and remdesivir (R)), anti-inflammatory (azithromycin (A) and dexamethasone (D)), and antithrombotic (enoxaparin (E) and heparin (H) drugs during they were hospitalized.

Results

The fibrotic features are found in 26 (70.3%) male subjects and 9 (10.1%) female subjects. The GGO are found in 25 (67.6%) male subjects and 9 (60.0%) female subjects. FDH are effective to reduce the pathologic features in HRCT related to fibrotic and GGO formations versus without FDH therapy, respectively 6 (85.7%) vs 28 (62.2%), (p=0.05) and 6 (85.7%) vs 27 (60.0%), (p=0.04)

Discussion

In COVID-19, FDH may reduce but GGO and fibrosis but the mechanisms are complex due to multifacorial involvements.

Conclusion

FDH is effective to reduced GGO and fibrosis. More analysis and future continuous research should be considered due to multifactorial influence to GGO and fibrotic lesion formations.